DE69329397D1 - Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons - Google Patents

Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons

Info

Publication number: DE69329397D1
Authority: DE; Germany
Prior art keywords: derivatives; stritial; neuron; promote; function
Prior art date: 1992-07-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69329397T

Other languages

English (en)

Other versions

DE69329397T2 (de

Inventor

Michael E Lewis

Nicola Neff

Jill Roberts-Lewis

Chikara Murakata

Hiromitsu Saito

Yuzuru Matsuda

James C Kauer

Marcie A Glicksman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

KH Neochem Co Ltd

Cephalon LLC

Original Assignee

Kyowa Hakko Kogyo Co Ltd

Cephalon LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-24

Filing date

1993-07-26

Publication date

2000-10-12

1993-07-26 Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd

2000-10-12 Publication of DE69329397D1 publication Critical patent/DE69329397D1/de

2001-03-15 Application granted granted Critical

2001-03-15 Publication of DE69329397T2 publication Critical patent/DE69329397T2/de

2013-07-27 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Psychology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DE69329397T 1992-07-24 1993-07-26 Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons Expired - Lifetime DE69329397T2 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US92010292A	1992-07-24	1992-07-24

Publications (2)

Publication Number	Publication Date
DE69329397D1 true DE69329397D1 (de)	2000-10-12
DE69329397T2 DE69329397T2 (de)	2001-03-15

Family

ID=25443161

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE69329397T Expired - Lifetime DE69329397T2 (de)	1992-07-24	1993-07-26	Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons
DE69333874T Expired - Lifetime DE69333874T2 (de)	1992-07-24	1993-07-26	Verwendung von vier K-252a Derivaten
DE69310178T Expired - Lifetime DE69310178T2 (de)	1992-07-24	1993-07-26	K-252a DERIVATE

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DE69333874T Expired - Lifetime DE69333874T2 (de)	1992-07-24	1993-07-26	Verwendung von vier K-252a Derivaten
DE69310178T Expired - Lifetime DE69310178T2 (de)	1992-07-24	1993-07-26	K-252a DERIVATE

Country Status (18)

Country	Link
US (1)	US5461146A (de)
EP (4)	EP0651754B1 (de)
JP (3)	JP3762427B2 (de)
KR (1)	KR100276008B1 (de)
AT (3)	ATE304848T1 (de)
AU (1)	AU675236B2 (de)
BR (1)	BR9306789A (de)
CA (1)	CA2140924A1 (de)
DE (3)	DE69329397T2 (de)
DK (3)	DK0651754T3 (de)
ES (3)	ES2101331T3 (de)
GR (2)	GR3023817T3 (de)
HK (1)	HK1028206A1 (de)
HU (5)	HU0301601D0 (de)
NO (2)	NO305481B1 (de)
NZ (2)	NZ254662A (de)
PT (1)	PT768312E (de)
WO (1)	WO1994002488A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5621101A (en) *	1992-07-24	1997-04-15	Cephalon, Inc.	Protein kinase inhibitors for treatment of neurological disorders
US5756494A (en) *	1992-07-24	1998-05-26	Cephalon, Inc.	Protein kinase inhibitors for treatment of neurological disorders
DE4243321A1 (de) *	1992-12-21	1994-06-23	Goedecke Ag	Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU679752B2 (en) *	1993-05-28	1997-07-10	Cephalon, Inc.	Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) *	1993-09-16	1995-11-21	Cephalon, Inc.	K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
ATE181049T1 (de) *	1993-12-07	1999-06-15	Lilly Co Eli	Synthese von bisindolylmaleimiden
US5624949A (en) *	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
US5541347A (en) *	1993-12-07	1996-07-30	Eli Lilly And Company	Synthesis of bisindolylmaleimides
US5843935A (en) *	1993-12-07	1998-12-01	Eli Lilly And Company	Protein kinase C inhibitors
ES2162843T3 (es) *	1993-12-07	2002-01-16	Lilly Co Eli	Inhibidores de la proteina quinasa c.
US5723456A (en) *	1993-12-07	1998-03-03	Eli Lilly & Company	Therapeutic treatment for cardiovascular diseases
CA2179650C (en) *	1993-12-23	2007-10-30	William Francis Heath, Jr.	Bisindolemaleimides and their use as protein kinase c inhibitors
WO1995022331A1 (en) *	1994-02-18	1995-08-24	Cephalon, Inc.	Aqueous indolocarbazole solutions
KR100464907B1 (ko) *	1994-10-26	2005-07-04	세파론, 인코포레이티드	신경계질환치료용단백질키나아제억제제
US5650407A (en) *	1995-04-05	1997-07-22	Cephalon, Inc.	Selected soluble esters of hydroxyl-containing indolocarbazoles
US5686444A (en) *	1995-04-05	1997-11-11	Cephalon, Inc.	Selected soluble esters of hydroxyl-containing indolocarbazoles
US5808060A (en) *	1995-12-11	1998-09-15	Cephalon, Inc.	Fused isoindolones
US6232299B1 (en)	1996-05-01	2001-05-15	Eli Lilly And Company	Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
AU2819397A (en) *	1996-05-07	1997-11-26	Presidents And Fellows Of Harvard College	Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
US6875865B1 (en) *	1996-06-03	2005-04-05	Cephalon, Inc.	Selected derivatives of K-252a
UA67725C2 (en)	1996-06-03	2004-07-15	Cephalon Inc	K-252a derivatives and a method for improvement of functioning and cell survival enhancement
BR9710693A (pt)	1996-06-25	2000-01-11	Cephalon Inc	Uso de um derivado de k-252a para o tratamento do nervo central ou periférico e super produção de citoquinona.
US7144997B2 (en) *	1997-07-24	2006-12-05	Curis, Inc.	Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
US5985877A (en) †	1997-08-15	1999-11-16	Cephalon, Inc.	Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
WO1999033836A1 (en)	1997-12-31	1999-07-08	Cephalon, Inc.	3'-epimeric k-252a derivatives
US6811992B1 (en)	1998-05-14	2004-11-02	Ya Fang Liu	Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) *	1998-06-05	2000-10-03	Cephalon, Inc.	Bridged indenopyrrolocarbazoles
US6013646A (en) *	1998-07-02	2000-01-11	Bayer Corporation	Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6200968B1 (en)	1998-08-06	2001-03-13	Cephalon, Inc.	Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) *	1998-08-06	2010-09-14	Cephalon, Inc.	Particle-forming compositions containing fused pyrrolocarbazoles
EP1126855B1 (de)	1998-09-25	2007-05-09	Cephalon, Inc.	Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
EP1121932A4 (de) *	1998-10-13	2001-12-19	Kyowa Hakko Kogyo Kk	Heilmittel für augenerkrankungen
US6242473B1 (en) *	1999-01-08	2001-06-05	Maxim Pharmaceuticals, Inc.	Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6841567B1 (en)	1999-02-12	2005-01-11	Cephalon, Inc.	Cyclic substituted fused pyrrolocarbazoles and isoindolones
KR20020027486A (ko)	1999-07-09	2002-04-13	오르토-맥네일 파마슈티칼, 인코퍼레이티드	신경영양성 피롤리딘 및 피페리딘, 및 그를 함유하는관련된 조성물
AU5606400A (en)	1999-07-09	2001-01-30	Ortho-Mcneil Pharmaceutical, Inc.	Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
WO2001042243A2 (en) *	1999-12-08	2001-06-14	Advanced Medicine, Inc.	Protein kinase inhibitors
US20020002169A1 (en)	1999-12-08	2002-01-03	Griffin John H.	Protein kinase inhibitors
US7129250B2 (en)	2000-05-19	2006-10-31	Aegera Therapeutics Inc.	Neuroprotective and anti-proliferative compounds
WO2002010768A2 (en) *	2000-07-31	2002-02-07	The Regents Of The University Of California	Model for alzheimer's disease and other neurodegenerative diseases
DE10113513A1 (de) *	2001-03-20	2002-10-02	Medinnova Ges Med Innovationen	Kombinationspräparat zur Prophylaxe und/oder Therapie von Nervenzell- und/oder Gliazellschäden durch ein neues Behandlungsverfahren
GB0117645D0 (en) *	2001-07-19	2001-09-12	Isis Innovation	Therapeutic stratergies for prevention and treatment of alzheimers disease
DE60213842T2 (de)	2001-10-30	2007-09-06	Novartis Ag	Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
US20050130877A1 (en) *	2003-03-14	2005-06-16	Children's Medical Center Corporation	Axon regeneration with PKC inhibitors
US6664266B2 (en) *	2002-03-14	2003-12-16	Children's Medical Center Corporation	Axon regeneration with PKC inhibitiors
CA2393720C (en)	2002-07-12	2010-09-14	Eli Lilly And Company	Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
DE10255343B4 (de) *	2002-11-27	2006-09-07	Nad Ag	N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
US20040175384A1 (en) *	2003-12-12	2004-09-09	Mohapatra Shyam S.	Protein kinase C as a target for the treatment of respiratory syncytial virus
AU2004262927B2 (en)	2003-08-08	2008-05-22	Novartis Ag	Combinations comprising staurosporines
US8592368B2 (en)	2003-12-19	2013-11-26	University Of South Florida	JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
AU2005217024B2 (en) *	2004-02-27	2011-03-24	Cephalon, Inc.	Crystalline forms of a pharmaceutical compound
WO2006020145A2 (en) *	2004-07-19	2006-02-23	The Johns Hopkins University	Flt3 inhibitors for immune suppression
CN100513850C (zh) *	2005-08-23	2009-07-15	浙江华夏阀门有限公司	三角截面密封套
PL1919979T5 (pl) *	2005-08-25	2017-10-31	Creabilis Therapeutics Spa	Polimerowe koniugaty K-252a i ich pochodne
TW200803849A (en)	2005-09-16	2008-01-16	Schering Corp	Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
BRPI0617236A2 (pt)	2005-10-11	2011-07-19	Merck Patent Gmbh	modulação da expressão de quimiocina, dependente de egfr, e influência sobre a terapia e diagnóstico de tumores e efeitos colaterais da mesma
US20100150944A1 (en) *	2007-04-16	2010-06-17	Modgene, Llc	Methods and compositions for diagnosis and treatment of depression and anxiety
WO2009067221A2 (en) *	2007-11-20	2009-05-28	Cephalon, Inc.	Microemulsion containing indolocarbazole compound and dosage forms containing the same
BR112015013849A2 (pt)	2012-12-21	2017-07-11	Sykehuset Soerlandet Hf	terapia direcionada a egfr de distúrbios neurológicos e dor
WO2019090205A1 (en) *	2017-11-06	2019-05-09	Snap Bio, Inc.	Pim kinase inhibitor compositions, methods, and uses thereof
WO2024018245A1 (en)	2022-07-22	2024-01-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of calpain inhibitors for the treatment of the diabetic kidney disease
WO2024153744A1 (en)	2023-01-20	2024-07-25	Institut National de la Santé et de la Recherche Médicale	Autophagy activators for the treatment of rhabdomyolysis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4554402A (en) *	1983-12-23	1985-11-19	Aluminum Company Of America	Vibration damper for overhead conductor
JPS62102388A (ja) *	1985-10-29	1987-05-12	Toppan Printing Co Ltd	Ｉｃカ−ド
JPS62155284A (ja) *	1985-12-27	1987-07-10	Kyowa Hakko Kogyo Co Ltd	生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) *	1985-12-27	1987-07-10	Kyowa Hakko Kogyo Co Ltd	生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja) *	1986-03-20	1987-09-28	Kyowa Hakko Kogyo Co Ltd	新規物質ｕｃｎ―０１
US4816450A (en) *	1986-09-15	1989-03-28	Duke University	Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) *	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) *	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
US4735939A (en) *	1987-02-27	1988-04-05	The Dow Chemical Company	Insecticidal activity of staurosporine
DE3752123T2 (de) *	1987-03-09	1998-05-14	Kyowa Hakko Kogyo Kk	Derivate des physiologisch aktiven mittels k-252
US5093330A (en) *	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) *	1987-06-15	1988-11-30	Ciba Geigy Ag	Derivatives substituted at methyl-amino nitrogen
JPH07113027B2 (ja) *	1987-12-24	1995-12-06	協和醗酵工業株式会社	Ｋ−２５２誘導体
JPH0725786A (ja) *	1990-05-16	1995-01-27	Univ Rockefeller	アルツハイマー病を伴うアミロイドーシスの治療
EP0593663A4 (en) *	1991-07-03	1996-10-30	Regeneron Pharma	Method and assay system for neurotrophin activity
DE4133605C2 (de) *	1991-10-10	1994-05-11	Siemens Ag	Flexibler Roboterarm
EP0610433A1 (de) *	1991-11-08	1994-08-17	The University Of Southern California	K-252 verbindungen enthaltende zusammensetzungen zur potenzierung der neurophinaktivität
DE4217964A1 (de) *	1992-05-30	1993-12-02	Goedecke Ag	Indolocarbazol-Imide und deren Verwendung

1993
- 1993-07-22 US US08/096,561 patent/US5461146A/en not_active Expired - Lifetime
- 1993-07-26 DE DE69329397T patent/DE69329397T2/de not_active Expired - Lifetime
- 1993-07-26 DE DE69333874T patent/DE69333874T2/de not_active Expired - Lifetime
- 1993-07-26 AT AT99120008T patent/ATE304848T1/de not_active IP Right Cessation
- 1993-07-26 CA CA002140924A patent/CA2140924A1/en not_active Abandoned
- 1993-07-26 ES ES93917337T patent/ES2101331T3/es not_active Expired - Lifetime
- 1993-07-26 EP EP93917337A patent/EP0651754B1/de not_active Expired - Lifetime
- 1993-07-26 HU HU0301601A patent/HU0301601D0/hu unknown
- 1993-07-26 DK DK93917337.3T patent/DK0651754T3/da active
- 1993-07-26 ES ES99120008T patent/ES2248950T3/es not_active Expired - Lifetime
- 1993-07-26 JP JP50473194A patent/JP3762427B2/ja not_active Expired - Lifetime
- 1993-07-26 EP EP96116661A patent/EP0768312B1/de not_active Expired - Lifetime
- 1993-07-26 DK DK96116661T patent/DK0768312T3/da active
- 1993-07-26 ES ES96116661T patent/ES2151629T3/es not_active Expired - Lifetime
- 1993-07-26 BR BR9306789A patent/BR9306789A/pt not_active Application Discontinuation
- 1993-07-26 NZ NZ254662A patent/NZ254662A/en not_active IP Right Cessation
- 1993-07-26 PT PT96116661T patent/PT768312E/pt unknown
- 1993-07-26 KR KR1019950700251A patent/KR100276008B1/ko not_active IP Right Cessation
- 1993-07-26 EP EP99120008A patent/EP1002534B1/de not_active Expired - Lifetime
- 1993-07-26 WO PCT/US1993/006974 patent/WO1994002488A1/en active IP Right Grant
- 1993-07-26 HU HU0301601A patent/HU225341B1/hu unknown
- 1993-07-26 DK DK99120008T patent/DK1002534T3/da active
- 1993-07-26 NZ NZ286198A patent/NZ286198A/en not_active IP Right Cessation
- 1993-07-26 HU HU9500192A patent/HU225297B1/hu unknown
- 1993-07-26 AU AU46881/93A patent/AU675236B2/en not_active Expired
- 1993-07-26 HU HU0301425A patent/HU0301425D0/hu unknown
- 1993-07-26 EP EP04025114A patent/EP1512688A1/de not_active Withdrawn
- 1993-07-26 HU HU0301425A patent/HU225342B1/hu unknown
- 1993-07-26 DE DE69310178T patent/DE69310178T2/de not_active Expired - Lifetime
- 1993-07-26 AT AT93917337T patent/ATE152111T1/de not_active IP Right Cessation
- 1993-07-26 AT AT96116661T patent/ATE196142T1/de not_active IP Right Cessation
1995
- 1995-01-23 NO NO950242A patent/NO305481B1/no not_active IP Right Cessation
1997
- 1997-06-19 GR GR970401455T patent/GR3023817T3/el unknown
1999
- 1999-02-05 NO NO990542A patent/NO307446B1/no not_active IP Right Cessation
2000
- 2000-11-21 HK HK00107421A patent/HK1028206A1/xx not_active IP Right Cessation
- 2000-11-28 GR GR20000402623T patent/GR3034917T3/el not_active IP Right Cessation
2002
- 2002-08-23 JP JP2002244111A patent/JP3723533B2/ja not_active Expired - Fee Related
2005
- 2005-01-27 JP JP2005019891A patent/JP2005170955A/ja active Pending

Also Published As

Publication number	Publication date
NZ286198A (en)	2001-06-29
JPH08501080A (ja)	1996-02-06
US5461146A (en)	1995-10-24
WO1994002488A1 (en)	1994-02-03
NO307446B1 (no)	2000-04-10
DE69310178D1 (de)	1997-05-28
NO990542L (no)	1999-02-05
EP0768312A3 (de)	1997-06-04
ATE196142T1 (de)	2000-09-15
GR3034917T3 (en)	2001-02-28
HU225341B1 (en)	2006-10-28
DE69333874T2 (de)	2006-05-04
ATE304848T1 (de)	2005-10-15
DK1002534T3 (da)	2006-01-23
HU0301601D0 (en)	2003-08-28
DE69333874D1 (de)	2006-02-02
HU225297B1 (en)	2006-09-28
ES2248950T3 (es)	2006-03-16
GR3023817T3 (en)	1997-09-30
NO950242L (no)	1995-03-07
AU4688193A (en)	1994-02-14
EP1002534A1 (de)	2000-05-24
EP0768312A2 (de)	1997-04-16
ES2151629T3 (es)	2001-01-01
HU0301425D0 (en)	2003-07-28
AU675236B2 (en)	1997-01-30
KR950702564A (ko)	1995-07-29
HU9500192D0 (en)	1995-03-28
DK0651754T3 (da)	1997-10-27
KR100276008B1 (ko)	2000-12-15
ATE152111T1 (de)	1997-05-15
NO950242D0 (no)	1995-01-23
CA2140924A1 (en)	1994-01-25
PT768312E (pt)	2001-03-30
HU225342B1 (en)	2006-10-28
DK0768312T3 (da)	2000-12-11
EP0651754A1 (de)	1995-05-10
NZ254662A (en)	1996-11-26
JP3723533B2 (ja)	2005-12-07
NO305481B1 (no)	1999-06-07
HK1028206A1 (en)	2001-02-09
DE69310178T2 (de)	1997-09-25
JP2005170955A (ja)	2005-06-30
EP0768312B1 (de)	2000-09-06
EP1512688A1 (de)	2005-03-09
EP0651754A4 (de)	1995-08-09
JP3762427B2 (ja)	2006-04-05
JP2003113184A (ja)	2003-04-18
EP1002534B1 (de)	2005-09-21
EP0651754B1 (de)	1997-04-23
NO990542D0 (no)	1999-02-05
DE69329397T2 (de)	2001-03-15
HUT71239A (en)	1995-11-28
ES2101331T3 (es)	1997-07-01
BR9306789A (pt)	1998-12-08

Publication	Publication Date	Title
DE69329397D1 (de)	2000-10-12	Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons
BR8902533A (pt)	1990-01-23	Processo e aparelho para o tratamento de lama de despejo de tinta
DE3779149D1 (de)	1992-06-25	Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE69433456D1 (de)	2004-02-05	Vorrichtung zum Klassifizieren von Herzrhythmen basierend auf der Morphologie des Elektrogramms
ES2062303T3 (es)	1994-12-16	Agentes antipsicoticos espirociclicos.
BR8804188A (pt)	1989-03-14	Processo para controlar a aspereza da superficie de um filme
EP0363415A4 (en)	1993-03-17	Compounds for the treatment of alzheimer's disease
SE9502893D0 (sv)	1995-08-21	Användning av kollagenas
FR2622841B1 (fr)	1992-03-06	Stylo industriel permettant d'utiliser des encres ou des peintures a solvants volatils conditionnees dans des recharges etanches
DE69127940D1 (de)	1997-11-20	Vorrichtung zum Begrenzen des Einschlagwinkels von Fahrzeugrädern
FI883759A0 (fi)	1988-08-12	C.12-modifierade etromycin a-derivat.
DE58908820D1 (de)	1995-02-09	Verwendung einer bekannten Vorrichtung zum Verschieben von Teilen.
DE69208008D1 (de)	1996-03-14	Verfahren zur Herstellung von 2-Amino-5,6-Dimethoxy Tetralin
ATE88707T1 (de)	1993-05-15	Antagonisten fuer den platelet-aktivierungsfaktor, phomactine genannt, ihre herstellung und verwendung.
FR2659255B1 (fr)	1995-05-24	Procede de traitement de regeneration de sable de fonderie usage lie principalement a l'argile.
FR2640154B1 (fr)	1991-01-25	Jouet de puericulture en forme de vehicule pour l'apprentissage de la marche
DE69404370D1 (de)	1997-08-28	Gelatinase A zur Behandlung von der Alzheimerschen Krankheit
DE69001988D1 (de)	1993-07-22	Behandlung des schocks mit cyclodextrin und dessen derivaten.
FR2629474B1 (fr)	1991-04-12	Procede d'electrosynthese de cetones benzyliques
BR9204370A (pt)	1994-05-10	Processo de descurtimento de recíduos de couro
MA21680A1 (fr)	1990-07-01	Appareil de levage dispose a l'avant d'un vehicule tracteur.

Legal Events

Date	Code	Title	Description
2001-09-27	8364	No opposition during term of opposition